Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Heparin Market, by Product Type (Unfractionated Heparin (UH), Low Molecular Weight Heparin (LMWH), and Ultra-low Molecular Weight Heparin (ULMW)), by Dosage Form (Injection and Solutions), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 9.4 billion in 2017, and is estimated to exhibit a CAGR of 5.1% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2602
Heparin is a complex drug, which is used as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures, in order to prevent and treat various types of blood clots and atrial fibrillation with embolization. Moreover, according to the CDC, around one million U.S. population are reported to die each year due to venous thromboembolism (VTE). Additionally, in June 2017, the U.S. FDA approved BEVYXXA (betrixaban) for prevention of venous thromboembolism (VTE) in adult patients, who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. Similarly, in December 2017, Mylan N.V., a global pharmaceutical company, received final approval from the U.S. FDA for its abbreviated new drug applications (ANDAs) for Heparin Sodium Injection USP, 1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL, and 20,000 USP/mL, all of which are packaged in multi-dose vials. Furthermore, in June 2018, Mylan N.V. launched Bivalirudin for injection, 250 mg single-dose vial, a generic version of Angiomax from the Medicines Company, in the U.S. The product is a direct thrombin inhibitor and is indicated for use as an anticoagulant.
China is a major producer and exporter of heparin. For instance, according to the Energy and Commerce Committee, heparin supply from China to Thailand and Hong Kong increased rapidly to over 40,000 kilograms and 28,000 kilograms respectively in 2016.
However, in 2017, Energy and Commerce Committee sent a letter to the U.S. Food and Drug Administration (FDA), sharing information and concerns regarding China’s market for heparin. Among the concerns reported, include surging exports of heparin to Hong Kong and Thailand, and the discovery of use of frozen pig intestines to make heparin by Chinese industry. Moreover, according to the committee, about 60% of the crude ingredients used to manufacture heparin in the U.S. are sourced from China, leaving the U.S. health care system vulnerable to fluctuations in its supply. With the U.S. reliance on China for heparin, FDA added heparin to its list of drug shortages in February 2018.
Browse 33 Market Data Tables and 21 Figures spread through 149 Pages and in-depth TOC on “Heparin Market, by Product Type (Unfractionated Heparin (UH), Low Molecular Weight Heparin (LMWH), and Ultra-low Molecular Weight Heparin (ULMW)), by Dosage Form (Injection, and Solutions), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”
To know the latest trends and insights related to heparin market Press Release, click the link below: https://bit.ly/3lJaPFL
Key Takeaways of the Heparin Market:
- The global heparin market is expected to exhibit at a CAGR of 5.1% over the forecast period (2018-2026), attributed to rising incidence of coronary heart disease, pulmonary embolism, and deep vein thrombosis. For instance, according to the CDC 2015 report, about 5 to 8% of the U.S. population inherited thrombophilias.
- Key players operating in the global heparin market include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2602
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837